Pharmacy Newsletter : April 2015 by Pharmacy Department,
eCommons@AKU
Pharmacy Newsletter Publications
4-2015
Pharmacy Newsletter : April 2015
Pharmacy Department
Aga Khan University Hospital
Follow this and additional works at: http://ecommons.aku.edu/pharmacy_newsletter
Part of the Pharmacy and Pharmaceutical Sciences Commons
Recommended Citation
Pharmacy Department, "Pharmacy Newsletter : April 2015" (2015). Pharmacy Newsletter. Book 7.
http://ecommons.aku.edu/pharmacy_newsletter/7
April, 2015 Vol. 1, Issue 01 NEWSLETTER
Newsletter advisory committee/members 
of Pharmacy & Therapeutic Committee
Editor-in-Chief
Dr Muhammad Khurshid, 
Chairman P & TC 
Editor 
Abdul Latif Sheikh, 
Director Pharmacy Services
Editorial Staff
Salwa Ahsan, Manager Pharmacy
Yasir Ali, Manager Pharmacy
Ale Zehra, Clinical Pharmacist 
Hafsah M Ashfaq, Pharmacist 
Sadaf Gul, Pharmacist 
Published by
Drug & Poison Information Centre
Department of Pharmacy Services 
Aga Khan University Hospital Stadium 
Road, P.O. box 3500, Karachi 74800, 
Pakistan 
Pharmacy Newsletter provides 
information regarding the decisions of P 
& TC, current concepts in drug therapy, 
warnings and cautions issued by various 
regulatory agencies, drug interactions, 
ADRs and matters related to drug usage.
Opinions expressed are of authors and 
does not necessarily represent AKUH’s 
view/recommendations.
Publication of this newsletter has been 
through an endowment grant from 
Pharmacist group of Ontario, Canada
Drug & Poison Information Centre, 
Tel: +92 21 34861504, 1506, 1477, 1479
Email: drug.information@aku.edu 
hospital.aku.edu/Karachi/dpic
Inside this Issue:
Medication Safety Alert................Page 1
FDA Drug Safety Podcast of the       
Year 2014:.....................................Page 3
Operational Quality and Patient Safety 
Indicators – 2014..........................Page 5
Pharmacy Staff Appreciation Evening, 
2014..............................................Page 8
PHARMACY
Medication Safety Alert | AKUH Un-fractioned 
Heparin Usage Guideline for Systemic 
Anticoagulation in Adults
Hafsah M. Ashfaq, Pharmacist 
High alert medications are an essential component of drug therapy, but 
they carry a significant risk of causing serious injuries or death to patients 
if used in error. Anticoagulants are also among “High Alert Medications.”   
Unfractionated heparin, low-molecular weight heparin, and warfarin 
are the frequently used anticoagulants. When used or omitted in error, 
anticoagulants can cause life-threatening or fatal bleeding or thrombosis.
The Aga Khan University hospital developed guideline that is 
implemented in all the patient care areas including ER in order to 
standardize the usage and monitoring of Heparin. The highlights of 
guideline are as follows:
Consult hematologist before starting Heparin if:
 l Epidural catheter in place 
 l Platelets < 50x109/L
 l aPTT > 79 seconds
 l DIC, TTP or HIT
 l Active bleeding
Bolus:
DVT/PE = 80 units/kg IV push (rounded to nearest 1000) Max. Dose = 
10,000 units.
TIA, ACS, MI & ischemic CVA = 60 units/kg IV push (rounded to nearest 
1000) Max. Dose= 5000 units.
Flow Chart for Heparin Protocol:
Obtain 
baseline 
aPTT, 
CBC and 
Cr
Perform 
Bleeding 
Risk 
assessment
(anx. 1.1 
available in 
the policy
Prepare 
dilution,
25,000 units 
heparin/ 500 
ml D5W and
NS 
Calculate 
initial dose/ 
bolus if 
required
(according 
to condition)
Calculate 
maintenance 
dose/ IV 
infusion
(according to 
condition)
Obtain aPTT 
after 6 hrs. 
adjust by 
Nomogram 
(Standard & 
Low traget 
Nomogram)
Check aPTT 
Q6h till 2 
consecutive 
goal readings 
achieved 
Monitor 
aPTT daily 
and platelet 
counts 
every 3rd 
Day.
 )
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Infusion:
DVT/PE = 18 units/kg/hr (Max initial rate is 2250 units/hr)
TIA, ACS, MI & ischemic CVA = 12 units/kg/hr (Max initial rate is 1000 units/hr)
Goal of Therapy/Target:
Until target aPTT is reached, labs are checked every 3-6 hours as per nomogram and corresponding dose is 
adjusted or hold as applicable.
 a. Standard Target indications (aPTT 50-80 sec):  
Atrial fibrillation, VTE (DVT/PE), Arterial thromboembolism, Peripheral vascular disease, Mechanical valve.
 b. Low Target Indications (aPTT 50-60 sec): 
Patients > 70 years of age, pulmonary hypertension, ischemic stroke in patients with atrial fibrillation, patients 
with ACS, patients receiving GPIIb-IIIa inhibitors or fibrinolytics.
Alerts:
 l Bleeding risk assessment is to be done by resident before starting therapy
 l Resident of a primary team will review heparin infusion order as per protocol (6hrly/ 3hrly)
 l Nurse will document the Date, Time of aPTT test & result on Heparin Infusion protocol worksheet as 
  per protocol (6hrly/ 3hrly). A nurse signature is required on the worksheet
 l Any adjustment in dose will be done by resident of a primary team only. A resident signature is   
  required on the worksheet
 l If aPTT >120 sec nurse will hold infusion and immediately inform resident and/or senior resident of a  
  primary team.
 l Recommended lab monitoring is to be done (aPTT daily 6 hrly, Platelets count every 3rd day)
 l Clinical monitoring (bruises, bleeding, hematoma, neurological status); every shift
 l Follow guideline while switching Heparin to/from other anticoagulants (Warfarin, Enoxaparin,   
  Fondaparinux, Rivaroxaban etc.). Gap of required hours must be maintained
 l Pharmacy will ensure that 2 anticoagulants are not dispensed together to the same patient
 l Avoid concomitant LMWH administration
 l Physician should delay heparin order as per below mentioned conditions. In case of deviation,   
  attending physician and/or team resident will contact pharmacy directly:
  P Tirofiban given in less than last 4-8 hrs
  P LMWH given in less than last 6 hrs
  P Streptokinase in less than last 24 hrs
  P Alteplase in less than last 24 hrs
 l Infusion will be prepared and dispensed by Pharmacy after checking aPTT. 
 l Standard dilution is 25000 units heparin per 500 ml D5W or NS i.e. 50 units/ml
Note:  The Reversal of Heparin overdose & Transition to other anticoagulants are described in the Heparin 
Guidelines. Details will soon be available on: http://portal.aku.edu/jcia/jcia-cpg.asp 
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Ziprasidone
Aspirin + 
Prasugrel/Clopidogrel
Omalizumab
Lidocaine  2%
Topical Acne 
Products
Olmesartan
Docetaxel
Testosterone 
Products
Corticosteroid
Sildenafil
Testosterone Products
Sodium Phosphate Drugs
Ziprasidone may cause Drug Reaction with Eosinophilia and Systemic 
Symptoms (DRESS) which starts with a rash leading to swollen lymph 
nodes, high eosinophil counts, inflammation of organs and even death. 
A Clinical trial is being evaluated which showed 30 months therapy with 
dual antiplatelet has decreased risk of heart attacks and clot formation in 
stents, but an increased risk of death as compared to 12 months therapy. 
The warning that Xolair, when used in the treatment of asthma, may 
cause problems in the blood vessels supplying to the brain has been added 
to the label. 
A box warning to Oral viscous Lidocaine 2% solution will soon be added 
to the label. Its use for teething pain in infants and young children can 
cause serious harm, including death.
Certain OTC topical acne products can cause rare but potentially life-
threatening allergic reactions or severe irritation. Consumers should seek 
medical attention if they experience such reaction.
There is no clear evidence of increased cardiovascular risks with the use 
of Olmesartan in diabetic patients.
The intravenous Docetaxel contains ethanol. Patients may experience 
intoxication during and after treatment.
Manufacturers of Testosterone Products are required to include a general 
warning about the risk of venous thromboembolism, including DVT and 
PE, on the labels.
Warnings about serious adverse effects like loss of vision, stroke, paraly-
sis and death with the use of epidural Corticosteroids are to be added to 
the label. 
It was clarified that Sildenafil is approved to treat Pulmonary Arterial 
Hypertension in adults, not in children.
Risk of stroke, heart attack, and death with use of   FDA 
approved testosterone products is being investigated.
More than one dose of Sodium Phosphate in a day can cause harm to the 
kidneys, heart, and even death. High Risk Patients: Children under 5 
(Oral form), under 2 years (Rectal Form), > 55 years old; Dehydrated, re-
nal compromised, Bowel Obstruction/inflamed and those on nephrotoxic 
drugs (NSAID, ARBs, ACEI, etc.)
December 11th 
November 16th 
September 26th
 
June 26th 
June 25th
 
June 24th 
June 20th
 
June 19th
 
April 23rd
March 31th 
January 31st 
January 8th 
S. No. Date Drug
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FDA Drug Safety Podcast of the Year 2014
Sadaf Gul, Pharmacist
Reference: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/
*Table includes only the podcast of those drugs available at local market.
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Resuscitation Fluids in Critical Illness 
Kashif Hussain, Clinical Specialist
Resuscitation fluids may be the most common intervention in critical car. However, there is scarce evidence to 
guide the best use of resuscitation fluids in the ICU.
Resuscitation Fluids in the ICU: Pearls
	 l There is no such thing as an ideal resuscitation fluid; they each have flaws, and none has been   
  demonstrated superior to the others in effectiveness or safety.
 l Any resuscitation fluid can contribute to interstitial edema, which may have detrimental effects on  
  ventilator weaning, cardiovascular function, wound healing, or other outcomes.
 l Although colloids have been believed to have superior “volume-expanding” effects over crystalloids,  
  any advantage of colloids in hemodynamic response appears to be minimal in practice.
 l Normal saline given in large quantities can cause a hyperchloremic metabolic acidosis, and has been  
  associated with renal injury.
 l Hydroxyethyl starches (HES) have harmful effects in many critically ill patients, and there seems to be  
  little justification for their continued use, or for other semisynthetic colloid solutions.
 l Albumin appears safe and may be helpful in early sepsis, but has no definite advantages, and is too  
  expensive to recommend as a standard resuscitation fluid.
	 l Hypertonic saline (used to avoid producing edema) has not yet been proven safe.
Saline is Not Normal (But it is cheap and effective)
Saline’s designation as “normal” was based on an erroneous calculation of the salt concentration in blood as 
0.9% back in 1882 (it’s actually 0.6%). Saline is nearly isotonic with extracellular fluid, but frequently causes 
a hyperchloremic metabolic acidosis; the excess chloride has been blamed for immune and renal function. It’s 
also a common reason for hypernatremia in hospitalized patients. 
However, saline is cheap, and is an effective resuscitation fluid; it’s by far the most widely used globally. 
Resuscitation Fluids: What’s inside?
Sodium (Na)
Chloride (Cl)
Potassium (K)
Calcium (Ca)
Magnesium (Mg)
Lactate
Acetate
Gluconate
Tonicity
145 mmol/L
128 mmol/L
none
none
none
none
none
none
 250 mOsml/L
154 mmol/L
154 mmol/L
none
none
none
none
none
none
308 mOsm/L
130 mmol/L
109 mmol/L
4 mmol/L
1.5 mmol/L
none
28 meq (28 mmol/L)
none
none
280 mOsm/L
140 mmol/L
98 mmol/L
5 mmol/L
none
3 mmol/L
none
27 mmol/L
23 mmol/L
Isotonic (294 mOsm/L)
Albumin (20%) Saline (0.9% NaCl) Lactated Ringer’s Plasma-Lyte
Albumin as a Resuscitation Fluid
Albumin has hemodynamic advantages over crystalloid solutions as a volume-expanding resuscitation fluid. 
Physiologic studies have suggested a 1:3 ratio of albumin to crystalloid to achieve the same intravascular 
volume. Some consider albumin a wise choice as a resuscitation fluid for patients considered to be more at 
risk for volume overload (e.g., congestive heart failure, liver failure, or end-stage-renal disease). Given its 
narrow margin of benefit, albumin is too expensive to be recommended as a standard resuscitation fluid.
Pharmacy Newsletter 5
Operational Quality and Patient Safety Indicators – 2014
Hafsah M. Ashfaq – Pharmacist
The quality indicators are measures of hospital quality and safety drawn from readily available hospital 
inpatient data. Hospitals use Quality Indicators (QIs) to identify potential concerns about quality and safety 
and track their performance over time. The indicator which Drug & Poison Information Centre (DPIC), 
Department of Pharmacy Services, AKUH uses to track the performance includes:
 l Renal Dose Adjustment
 l Carbapenem Interchange policy
 l IV to PO Switch
 l Therapeutic Drug Monitoring (TDM) of narrow therapeutic index drugs
 l ADR identification through Triggers & Markers
Pharmacist at Drug & poison information center (DPIC) performs these activities daily and intervenes 
according to recommendation from different guidelines & resources.
l	Renal Dose adjustment is a major component of the operational quality indicators. Kidneys are the major 
route of elimination for most of the drugs. In patients with renal impairment, CKD or AKI accumulation 
of drug metabolites can cause adverse drug reactions, so the dosages must be adjusted according to renal 
function.
Patient having deranged creatinine are searched daily and their doses are adjusted according to creatinine 
clearance and during the last year 100% interventions accepted for renal dose adjustment.
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l	Carbapenem interchange policy has been approved by Antibiotics Subcommittee as well as Hospital 
Pharmacy and Therapeutic Committee (P & TC), an oversight committee of the Antibiotics Subcommittee. 
Primary reasons have been the cost per gram of the Meropenem (estimated savings of Rs.1500-2000 per day 
depending on dose), identical and similarity of spectrum and usage in approved indication. 
Exclusion criteria (Meropenem indication): 
 l  Pediatric age group 
 l  Known case of epilepsy or having seizures
  l  CNS infections 
 l  Head trauma/injury (conditions in which seizure threshold may decrease) 
All the patients on Meropenem (except the exclusions mentioned above) are reviewed and advised for switching 
from Meropenem to Imipenem. Below is the graphical representation of percentage compliance in the Year 2014.
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l	IV to PO switch is the prompt conversion of IV antibiotic therapy to Oral. Patients may be considered can-
didates for switching from IV to Oral therapy once the patient has shown clinical improvement and is medi-
cally stable. It helps in:
	 l Reduction in the likelihood of hospital acquired bacteremia and infected/phlebitic IV lines. 
	 l Saves both medical and nursing time 
	 l Earlier hospital discharge. 
 l Significantly reduce treatment costs. 
 l Potential reduction in the risk of adverse effects; errors in preparation are significantly higher with  
  parenteral drugs, compared to oral formulation
 Medicines that have more than 80% oral bioavailability are switched from IV to PO. 
 All the patients on selected drugs are reviewed according to the criteria defined and suggested to shift from  
 IV to PO route. The graph below shows the compliance rate for the year 2014.
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Benchmark
l	Therapeutic drug monitoring is necessary for the narrow therapeutic index drugs to evaluate their doses 
and therapeutic response. Narrow therapeutic drug have narrow margin of safety so it is recommended to 
monitor their serum concentration prior to direct clinical observation. Drugs included in TDM are digoxin, 
theophylline, warfarin & Phenytoin. Pharmacists check the profile and if required suggest the physician 
for proper time to draw drug levels. Below graph for last year shows the percentage of patients required 
interventions for doses to be changed with respect to the serum drug concentrations.
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l	Triggers and Markers Pharmacy maintains the record of adverse drug reactions reported and takes the 
follow up. On monthly basis summary of ADRs is prepared for review by P&TC to take necessary action 
for safety. Trigger and markers is an activity in which the tracking of an ADR is done by the stat shots of 
particular agents that are used to reduce the adverse effects produced by a certain drug e.g. IV Pheniramine for 
an allergic reaction produced by cephalosporin or IV protamine given for heparin overdose etc. Following are 
the numbers of ADRs reported to DPIC in year 2014.
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Proud to Report
Polio Eradication Awareness Campaign
Pakistan is amongst the three countries where poliomyelitis (polio) is still categorized as an endemic.  WHO advisory in month of April 2014 
also impose that every traveler of Pakistan has to be vaccinated with polio vaccine. Department of Pharmacy Services, The Aga Khan University 
Hospital started Polio eradication campaign to spread awareness and to encourage public to participate in Government Polio Campaigns.
2 DROPS OF POLIO VACCINE, EVERY CHILD, EVERY TIME.
POLIO - FREE PAKISTAN : A DREAM MUST COME TRUE!
A PUBLIC SERVICE MESSAGE BY IMMUNIZATION SERVICES, MANAGED BY DEPARTMENT OF PHARMACY, AKUH
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Pharmacy Staff Appreciation Evening, 2014 
Pharmacy staff appreciation evening 2014 was held on Sunday 1st Feb, 2015 at the Sports and Rehabilitation Centre. At the event various thought 
provoking skits, songs and parodies were presented. Awards were distributed to the best nominees & outstanding achievers of 2014. A video title 
“Pharmacy achievements 2014” was especially made having the achievements of AKUH Pharmacy in 2014. 
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The Aga Khan University Hospital, Karachi
Newsletter Feedback 
Please help us improve our newsletter by filling the online feedback form through below link:
https://docs.google.com/forms/d/1ic4R7RJZcco6x8zHpFc6PZhM4HpjmDWUcVyRs1yVjzM/viewform?usp=send_form
